Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Medical Developments International Limited	
ABN	14 106 340 667	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr. Robert Maxwell Johnston
Date of last notice	8 April 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	JONDOL PTY LTD - Superannuation Fund	
Date of change	7 October 2016	
No. of securities held prior to change	30,131	
Class	Fully Paid Ordinary Shares	
Number acquired	114	
Number disposed	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	114 shares @ \$5.26 via participation in the Dividend Reinvestment Plan	
No. of securities held after change	30,245	

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares via participation in the MVP Dividend Reinvestment Plan announced on 18 August 2016.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Medical Developments International Limited
ABN	14 106 340 667

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Allan McCallum
Date of last notice	8 April 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mullacam Pty Ltd - 381,690
Date of change	7 October 2016
No. of securities held prior to change	381,690
Class	Fully Paid Ordinary Shares
Number acquired	1,450
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1,450 shares @ \$5.26 via participation in the Dividend Reinvestment Plan
No. of securities held after change	383,140

⁺ See chapter 19 for defined terms.

Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in	es via participation in the end Reinvestment Plan 18 August 2016.
---	---

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Medical Developments International Limited
ABN	14 106 340 667

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr. Philip Powell
Date of last notice	8 April 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Indirect
Nature of indirect interest	PNSF Pty Ltd as trustee for the Prime
(including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Numbers Superannuation Fund
Date of change	7 October 2016
No. of securities held prior to change	253,180
Class	Fully Paid Ordinary Shares
Number acquired	962
Number disposed	Nil
Value/Consideration	962 shares @ \$5.26 via participation in the
Note: If consideration is non-cash, provide details and estimated valuation	Dividend Reinvestment Plan
No. of securities held after change	254,142

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares via participation in the MVP Dividend Reinvestment Plan announced on 18 August 2016.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Medical Developments International Limited
ABN	14 106 340 667

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Leon Hoare
Date of last notice	8 April 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr. Leon Hoare
Date of change	7 October 2016
No. of securities held prior to change	10,043
Class	Fully Paid Ordinary Shares
Number acquired	38
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	38 shares @ \$5.26 via participation in the Dividend Reinvestment Plan
No. of securities held after change	10,081

⁺ See chapter 19 for defined terms.

Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in	sue of shares via participation in the VP Dividend Reinvestment Plan nnounced on 18 August 2016.
---	--

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N-+ 1' 1-1-
Detail of contract	Not applicable
Nature of interest	
N	
Name of registered holder	
(if issued securities)	
Date of change	
•	
Marandalara da anathira	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in	
relation to which the interest has changed	
Interest acquired	
interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details	
and an estimated valuation	
Interest after change	
	1

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Medical Developments International Limited
ABN	14 106 340 667

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Harry Oxer
Date of last notice	27 June 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dr. Harry Frank Oxer
Date of change	7 October 2016
No. of securities held prior to change	191,622
Class	Fully Paid Ordinary Shares
Number acquired	728
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	728 shares @ \$5.26 via participation in the Dividend Reinvestment Plan
No. of securities held after change	192,350

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares via participation in the MVP Dividend Reinvestment Plan announced on 18 August 2016.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Medical Developments International Limited
ABN	14 106 340 667

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Williams
Date of last notice	8 April 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Lawn Views Pty Ltd - Indirect Moggs Creek Pty Ltd - Indirect Mr. David Williams (Trustee) - Indirect Kidder Peabody Pty Ltd - Indirect Ward Williams - Indirect Saul Williams - Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Lawn Views Pty Ltd - 7,870,172 Moggs Creek Pty Ltd - 8,074,651 Mr. David Williams (Trustee) - 828,543 Kidder Peabody Pty Ltd - 1,004,391 Ward Williams - 23,548 Saul Williams - 8,550
Date of change	7 October 2016
No. of securities held prior to change	17,809,855
Class	Fully Paid Ordinary Shares
Number acquired	67,685
Number disposed	Nil

⁺ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	67,685 shares @ \$5.26 via participation in the Dividend Reinvestment Plan.
No. of securities held after change	17,877,540
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares via participation in the MVP Dividend Reinvestment Plan announced on 18 August 2016.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
	1 tot applicable
N. d. d. d.	
Nature of interest	
Name of registered holder	
(if issued securities)	
,	
Date of change	
3 9.	
No and does of according to the	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
relation to which the interest has changed	
Interest acquired	
•	
Interest disposed	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details	
and an estimated valuation	
Interest after change	
interest after change	

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.